<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025194</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068935</org_study_id>
    <secondary_id>MSKCC-01064</secondary_id>
    <secondary_id>MSKCC-01064A</secondary_id>
    <secondary_id>NCI-3634</secondary_id>
    <nct_id>NCT00025194</nct_id>
  </id_info>
  <brief_title>Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer</brief_title>
  <official_title>A Phase I And Randomized Phase 2 Trial Of Epothilone B Analogue BMS 247550 (NSC # 710428) Administered Every 21 Days With Or Without Oral Estramustine Phosphate In Patients With Androgen Independent Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as ixabepilone and estramustine, use different&#xD;
      ways to stop tumor cells from dividing so they stop growing or die. It is not yet known&#xD;
      whether BMS-247550 is more effective with or without estramustine in treating prostate&#xD;
      cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase I/II trial is studying the best dose of ixabepilone when given&#xD;
      together with estramustine and to see how well giving ixabepilone together with estramustine&#xD;
      works compared to ixabepilone alone in treating patients with progressive prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of ixabepilone combined with estramustine in&#xD;
           patients with progressive androgen-independent adenocarcinoma of the prostate. (Phase I)&#xD;
&#xD;
        -  Compare the safety and efficacy of ixabepilone with or without estramustine in this&#xD;
           patient population. (Phase II)&#xD;
&#xD;
        -  Correlate the clinical outcomes with reverse transcriptase-polymerase chain&#xD;
           reaction-based assay for prostate-specific antigen mRNA in patients treated with these&#xD;
           regimens.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of ixabepilone (phase I) followed by a randomized,&#xD;
      multicenter study (phase II).&#xD;
&#xD;
        -  Phase I: Patients receive ixabepilone IV over 3 hours on day 2 and oral estramustine 3&#xD;
           times daily on days 1-5. Courses repeat every 3 weeks in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of ixabepilone until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
        -  Phase II: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
             -  Arm I: Patients receive ixabepilone IV over 3 hours at the MTD on day 2 and&#xD;
                estramustine as in phase I.&#xD;
&#xD;
             -  Arm II: Patients receive ixabepilone IV over 3 hours at the MTD on day 1. Treatment&#xD;
                in both arms repeats as in phase I.&#xD;
&#xD;
      Patients are followed every 12 weeks until disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-12 patients will be accrued for phase I of this study and a&#xD;
      total of 44-92 patients (22-46 per treatment arm) will be accrued for phase II of this study&#xD;
      within 12-18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2001</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estramustine phosphate sodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ixabepilone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          -  Must have disease progression meeting 1 of the following criteria:&#xD;
&#xD;
               -  Rising prostate-specific antigen (PSA) on at least 3 consecutive measurements&#xD;
                  taken more than 1 week apart&#xD;
&#xD;
               -  Measurable disease, defined as new or progressive soft tissue masses on CT scan&#xD;
                  or MRI&#xD;
&#xD;
               -  New metastatic lesions by radionuclide bone scan&#xD;
&#xD;
          -  The most recent PSA must be at least 4 ng/mL if no measurable disease is present&#xD;
&#xD;
          -  Ineligible if sole manifestation of progressive disease is an increase in&#xD;
             disease-related symptoms&#xD;
&#xD;
          -  Serum testosterone no greater than 50 ng/mL&#xD;
&#xD;
          -  One of the following therapies for maintenance of castrate status required:&#xD;
&#xD;
               -  Must continue on gonadotropin-releasing hormone analogs (e.g., leuprolide or&#xD;
                  goserelin) to maintain castrate levels of serum testosterone&#xD;
&#xD;
                    -  Developed disease progression after discontinuation of the antiandrogen that&#xD;
                       was part of the first-line hormonal therapy&#xD;
&#xD;
               -  Prior surgical orchiectomy&#xD;
&#xD;
          -  Developed disease progression after discontinuation of megestrol&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  No history of bleeding disorder that would preclude anticoagulation with warfarin&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  PT/PTT normal (unless anticoagulated for other reasons [e.g., atrial fibrillation])&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No significant cardiovascular disease&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  No active unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No history of hemorrhagic or thrombotic cerebrovascular accident or deep venous&#xD;
             thrombosis within the past 6 months&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No pulmonary embolism within the past 6 months&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No history of allergic reactions to compounds of similar chemical or biological&#xD;
             composition to the epothilones&#xD;
&#xD;
          -  No history of recent gastrointestinal bleeding that would preclude anticoagulation&#xD;
             with warfarin&#xD;
&#xD;
          -  No other concurrent active malignancy except nonmelanomatous skin cancer&#xD;
&#xD;
               -  Disease not considered currently active if completely treated with less than a&#xD;
                  30% risk for relapse&#xD;
&#xD;
          -  No other concurrent uncontrolled illness&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent routine filgrastim (G-CSF) or sargramostim (GM-CSF) except for&#xD;
             neutropenic fever&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior palliative radiotherapy to more than 25% of bone marrow&#xD;
&#xD;
          -  No prior radioisotope therapy with strontium chloride Sr 89 or samarium Sm 153&#xD;
             lexidronam pentasodium&#xD;
&#xD;
          -  No concurrent therapeutic radiotherapy&#xD;
&#xD;
          -  Concurrent focal radiotherapy for palliation of bone disease-related symptoms allowed&#xD;
             at the investigator's discretion&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent anticancer investigational or commercial agents or therapies&#xD;
&#xD;
          -  No concurrent herbal, alternative, or food supplements (e.g., PC-SPES, saw palmetto,&#xD;
             or St. John's Wort)&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No initiation of bisphosphonates immediately before or during study&#xD;
&#xD;
          -  Concurrent bisphosphonates allowed if developed disease progression while on stable&#xD;
             doses&#xD;
&#xD;
          -  Concurrent daily multivitamin allowed&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Morris, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, Martone L, Curley T, Delacruz A, Scher HI, Kelly WK. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol. 2005 Mar 1;23(7):1439-46.</citation>
    <PMID>15735119</PMID>
  </results_reference>
  <results_reference>
    <citation>Smaletz O, Galsky M, Scher HI, DeLaCruz A, Slovin SF, Morris MJ, Solit DB, Davar U, Schwartz L, Kelly WK. Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. Ann Oncol. 2003 Oct;14(10):1518-24.</citation>
    <PMID>14504052</PMID>
  </results_reference>
  <results_reference>
    <citation>Smaletz O, Kelly WK, Horse-Grant D, et al.: Epothilone B analogue (BMS-247550) with estramustine phosphate (EMP) in patients (pts) with progressive castrate-metastatic prostate cancer (PC). [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-732, 184a, 2002.</citation>
  </results_reference>
  <verification_date>November 2005</verification_date>
  <study_first_submitted>October 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 20, 2013</last_update_submitted>
  <last_update_submitted_qc>June 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2013</last_update_posted>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estramustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

